Cidara Therapeutics Inc (CDTX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Cidara Therapeutics Inc (NASDAQ:CDTX) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $14.28.

A number of brokerages have recently issued reports on CDTX. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 28th. HC Wainwright boosted their price target on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Zacks Investment Research upgraded shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research note on Wednesday, October 25th. Finally, ValuEngine lowered shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

Shares of Cidara Therapeutics (CDTX) traded up $0.05 during trading hours on Tuesday, hitting $7.20. 65,900 shares of the stock were exchanged, compared to its average volume of 101,935. Cidara Therapeutics has a 1-year low of $5.60 and a 1-year high of $11.75. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $143.69 and a PE ratio of -2.12.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.21. equities research analysts forecast that Cidara Therapeutics will post -3.31 earnings per share for the current fiscal year.

In related news, major shareholder Target N. V. Biotech bought 60,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were bought at an average cost of $7.57 per share, for a total transaction of $454,200.00. Following the completion of the transaction, the insider now owns 2,295,272 shares of the company’s stock, valued at approximately $17,375,209.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 18.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in CDTX. Broadfin Capital LLC grew its position in shares of Cidara Therapeutics by 45.0% in the second quarter. Broadfin Capital LLC now owns 816,275 shares of the biotechnology company’s stock valued at $6,122,000 after purchasing an additional 253,400 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Cidara Therapeutics during the second quarter valued at approximately $650,000. BB Biotech AG lifted its stake in shares of Cidara Therapeutics by 5.6% during the second quarter. BB Biotech AG now owns 1,102,578 shares of the biotechnology company’s stock valued at $8,269,000 after buying an additional 58,754 shares during the period. Susquehanna International Group LLP purchased a new position in shares of Cidara Therapeutics during the second quarter valued at approximately $350,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Cidara Therapeutics by 77.4% during the third quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 18,001 shares during the period. Institutional investors and hedge funds own 55.45% of the company’s stock.

WARNING: “Cidara Therapeutics Inc (CDTX) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/12/26/cidara-therapeutics-inc-cdtx-given-consensus-recommendation-of-buy-by-brokerages.html.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

What are top analysts saying about Cidara Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cidara Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit